Health Affairs August 25, 2023
Troyen A. Brennan, William H. Shrank

So rare is bipartisan regulatory legislation in Congress, especially in health care, that when it occurs one must presume it is in response to prohibitive costs to society or a threat to patient welfare. Pharmacy benefit managers (PBMs) seem to be considered both, as no fewer than eight separate bills to change PBM practices have recently been introduced or advanced out of committee, all of them involving both Democratic and Republican co-sponsors. This remarkable collaboration, following on the heels of the historic, and decidedly partisan, decision to allow the Centers for Medicare and Medicaid Services (CMS) to negotiate medication prices, deserves careful policy analysis.

Pharmacy Benefit Management Tools And Strategies

PBMs are a relatively new addition to the health policy...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: CMS, Congress / White House, Govt Agencies, Insurance, Medicare, Pharma, Pharma / Biotech, Regulations
4 top healthcare CIOs: Forbes
Trace Neuroscience Nets $101M in Series A Funding for ALS, Dementia Therapy Development
RFK Jr. vs. Vivek: Trump world's two paths for pharma regulation
Managing the Specialty Drug Cost Challenge: Is Your Pharmacy Benefits Strategy Ready for 2025?
AI in Pharma: Where, When, and How Executives are Considering it

Share This Article